{"filing":{"accession_number":"0001193125-26-342334","cik":"0001750284","ticker":"OLMA","company_name":"Olema Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"olma-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-20260810.htm"},"events":[{"id":26528,"run_id":24114,"accession_number":"0001193125-26-342334","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $63.2 million, R\u0026D and G\u0026A expenses, cash position of $461.1 million, and operating metrics. The filing also reports material clinical progress (OPERA-01 enrollment completion, OP-3136 Phase 1 data, Bayer collaboration), which are typical components of a biopharmaceutical company's earnings disclosure.","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27682,"accession_number":"0001193125-26-342334","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $63.2 million, R\u0026D and G\u0026A expenses, cash position of $461.1 million, and operating metrics. The filing also reports material clinical progress (OPERA-01 enrollment completion, OP-3136 Phase 1 data, Bayer collaboration), which are typical components of a biopharmaceutical company's earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:09:11.033105+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27682,"accession_number":"0001193125-26-342334","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $63.2 million, R\u0026D and G\u0026A expenses, cash position of $461.1 million, and operating metrics. The filing also reports material clinical progress (OPERA-01 enrollment completion, OP-3136 Phase 1 data, Bayer collaboration), which are typical components of a biopharmaceutical company's earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:09:11.033105+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-08-10"}]}